Abstract
Hypoxia is a fetal stressor that leads to the production of endothelin-1 (ET-1). Previous work has shown that ET-1 treatment leads to the premature terminal differentiation of fetal cardiomyocytes. However, the precise mechanism is unknown. We tested the hypothesis that the fetal cardiomyocyte proteome will be greatly altered due to ET-1-treatment, which reveals a potential molecular mechanism of ET-1-induced terminal differentiation. Over a thousand proteins were detected in the fetal cardiomyocytes and among them 75 proteins were significantly altered due to ET-1 treatment. Using IPA pathway analysis, the merged network depicted several key proteins that appeared to be involved in regulating proliferation, including: EED, UBC, ERK1/2, MAPK, Akt, and EGFR. EED protein, which is associated with regulating proliferation via epigenetic mechanisms, is of particular interest. Herein we propose a model of the molecular mechanism by which ET-1 induced cardiomyocyte terminal differentiation occurs.
Keywords: Cardiomyocyte, Endothelin-1, EED, Fetal, Heart, Proliferation, Proteome.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Volume: 17 Issue: 15
Author(s): Alexandra N. Shin, Chiranjib Dasgupta, Guangyu Zhang, Kala Seal and Lubo Zhang*
Affiliation:
- Center for Perinatal Biology, Division of Pharmacology, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350,United States
Keywords: Cardiomyocyte, Endothelin-1, EED, Fetal, Heart, Proliferation, Proteome.
Abstract: Hypoxia is a fetal stressor that leads to the production of endothelin-1 (ET-1). Previous work has shown that ET-1 treatment leads to the premature terminal differentiation of fetal cardiomyocytes. However, the precise mechanism is unknown. We tested the hypothesis that the fetal cardiomyocyte proteome will be greatly altered due to ET-1-treatment, which reveals a potential molecular mechanism of ET-1-induced terminal differentiation. Over a thousand proteins were detected in the fetal cardiomyocytes and among them 75 proteins were significantly altered due to ET-1 treatment. Using IPA pathway analysis, the merged network depicted several key proteins that appeared to be involved in regulating proliferation, including: EED, UBC, ERK1/2, MAPK, Akt, and EGFR. EED protein, which is associated with regulating proliferation via epigenetic mechanisms, is of particular interest. Herein we propose a model of the molecular mechanism by which ET-1 induced cardiomyocyte terminal differentiation occurs.
Export Options
About this article
Cite this article as:
Shin N. Alexandra, Dasgupta Chiranjib, Zhang Guangyu, Seal Kala and Zhang Lubo*, Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation, Current Topics in Medicinal Chemistry 2017; 17 (15) . https://dx.doi.org/10.2174/1568026617666161116142417
DOI https://dx.doi.org/10.2174/1568026617666161116142417 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets New Insights in Research About Acute Ischemic Myocardial Injury and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design p53 Regulation of Energy Metabolism and Mitochondria Regulation of p53 in Cancer Cells: An Insight into the Role of Manganese Superoxide Dismutase
Current Pharmaceutical Biotechnology Stem Cells and Cardiovascular Repair: A Role for Natural and Synthetic Molecules Harboring Differentiating and Paracrine Logics
Cardiovascular & Hematological Agents in Medicinal Chemistry Life-history Constraints on the Mechanisms that Control the Rate of ROS Production
Current Genomics High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery Editorial from Editor-in-Chief [Cheyne-Stokes: A Flashback to the 19th Century]
Current Respiratory Medicine Reviews Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Epidermolysis Bullosa: The Pediatricians Role
Current Pediatric Reviews Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Exercise-induced Physiological Hypertrophy: Insights from Genomics
Current Genomics A Mitochondrial Approach to Cardiovascular Risk and Disease
Current Pharmaceutical Design Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets (Discontinued) Association Between Hypothyroidism and Takotsubo Cardiomyopathy: Analysis of Nationwide Inpatient Sample Database
Reviews on Recent Clinical Trials Mechanisms of Enhanced Vasoconstriction in the Mouse Model of Atherosclerosis: the Beneficial Effects of Sildenafil
Current Pharmaceutical Biotechnology